Creative Planning Has $1.84 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Creative Planning reduced its position in Exelixis, Inc. (NASDAQ:EXEL) by 1.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 70,934 shares of the biotechnology company’s stock after selling 766 shares during the period. Creative Planning’s holdings in Exelixis were worth $1,841,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Park Place Capital Corp acquired a new stake in shares of Exelixis during the second quarter worth $45,000. GAMMA Investing LLC grew its stake in shares of Exelixis by 107.9% during the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 1,041 shares during the period. EntryPoint Capital LLC grew its stake in shares of Exelixis by 537.2% during the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,746 shares during the period. Essex Investment Management Co. LLC acquired a new stake in shares of Exelixis during the third quarter worth $74,000. Finally, Blue Trust Inc. grew its stake in shares of Exelixis by 81.4% during the second quarter. Blue Trust Inc. now owns 3,953 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 1,774 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. TD Cowen lifted their price objective on Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Exelixis in a research note on Wednesday, September 18th. Royal Bank of Canada lifted their target price on Exelixis from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. UBS Group initiated coverage on Exelixis in a report on Thursday, September 19th. They set a “neutral” rating and a $30.00 target price on the stock. Finally, Bank of America lifted their target price on Exelixis from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Exelixis has a consensus rating of “Moderate Buy” and a consensus target price of $29.57.

Exelixis Price Performance

Shares of Exelixis stock opened at $28.50 on Tuesday. The firm has a market cap of $8.13 billion, a price-to-earnings ratio of 24.57, a price-to-earnings-growth ratio of 0.61 and a beta of 0.54. The stock’s 50-day moving average is $26.65 and its 200-day moving average is $24.05. Exelixis, Inc. has a one year low of $19.20 and a one year high of $29.75.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.44. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. The business had revenue of $637.18 million for the quarter, compared to analyst estimates of $468.21 million. On average, equities analysts expect that Exelixis, Inc. will post 1.58 EPS for the current year.

Insider Buying and Selling

In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $26.38, for a total transaction of $659,500.00. Following the transaction, the executive vice president now owns 605,325 shares of the company’s stock, valued at $15,968,473.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Exelixis news, EVP Dana Aftab sold 95,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the transaction, the executive vice president now owns 520,990 shares of the company’s stock, valued at $13,024,750. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $26.38, for a total value of $659,500.00. Following the transaction, the executive vice president now directly owns 605,325 shares in the company, valued at approximately $15,968,473.50. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 327,858 shares of company stock worth $8,640,129. Corporate insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.